Biotech Values

[Mufaso]

As I understand it they want a type C meeting and "Type C meetings are reserved for issues that do not fit in categories A or B. An example would be that type C and can be used to consult on the use of a biomarker as a new surrogate endpoint that has never before been used."

So if anything would argue for a type C meeting, it would be the NASH drug not the Obesity drug. That way Viking could argue for non invasive testing if they had an emphasis on NASH. Yet here they want it for the Obesity drug?

Not sure why they wouldn't have a normal end of phase to meeting with FDA on the obesity drug. Overall the body language tells me Management is emphasizing Obesity or at least paying more attention to it. Also throughout the call it just seemed that VK2735 took center stage. Maybe it's the timing of readouts. Or maybe I'm off base on this one.